Senescence is an inevitable consequence of life. As a result of exposure to intrinsic as well as extrinsic aging factors, cellular aging is triggered in stem cells (SCs) by gradually accumulating DNA damage due to the action of reactive oxygen species and epigenetic changes. 1 Thus, aging can be envisioned at the cellular level, as a result of altered cell function in response to changes in DNA structure that directly affects proper gene expression. In addition, SCs also aged by an intrinsic mechanism encoded by the phenomenon of telomere shortening. 2 Several well-known risk factors, such as obesity, diabetes and lack of physical activity that lead to atherosclerosis of the cardio-vascular system and impair the function of vital organs (for example, heart, kidney or brain), limit the overall lifespan. It is obvious that all these risk factors somehow must ultimately have an impact on the basic units of tissue rejuvenation, which are SCs. 1 They can directly affect SCs or damage the niches in which these cells reside and thereby impair SC self-renewal and differentiation. On the other hand, these risk factors may also lead to enhanced turnover/proliferation of SCs, resulting in premature exhaustion of these cells. The elucidation of these precise mechanisms will help to develop more efficient antiaging strategies.
Evidence accumulates that increase in calorie uptake and insulin/insulin-like growth factor (Ins/Igf) level in peripheral blood (PB) accelerates aging. [3] [4] [5] [6] [7] [8] On the other hand, calorie restriction and decrease in Ins/Igf signaling increases lifespan in worms, flies and mammals. Furthermore, insulin-like growth factor-1 (Igf1), insulin-like growth factor-2 (Igf2) and insulin (Ins) are described as stimulators of proliferation of normal and malignant hematopoietic stem progenitor cells (HSPCs). 9 While Igf1 and Igf2 signal through tyrosine kinase receptor Igf1R, Ins together with Igf2 may activate classical insulin receptor (InsR) and all factors together may activate a hybrid Igf1R/InsR. In contrast, Igf2R serves as a 'decoy receptor' that prevents Igf2 from binding to Igf1R or InsR. While Ins is secreted after calorie uptake from pancreatic islands, Igf1 (known also as somatomedin-C) is secreted from the liver into PB in a growth hormone (GH)-dependent manner. 8 Interestingly, the expression levels of Igf2, Igf2R and Rasgrf1 (a small GTP exchange factor for Ras protein that is involved in Ins/Igf signaling) are regulated by changes in somatic imprinting. The imprinted genes have a crucial role in embryogenesis, fetal growth, the totipotential state of the zygote and the pluripotency of developmentally early SCs. 10 The expression of imprinted genes is regulated by DNA methylation within differential methylated regions (DMRs), which are CpG-rich cis-elements within their gene loci.
Recently, our group demonstrated that adult tissues including the bone marrow (BM) harbor a population of pluripotent Oct4
À very small embryonic-like SCs (VSELs), 11 and postulated that these pluripotent SCs are deposited during early embryogenesis as a backup for long-term re-populating hematopoietic SCs (LT-HSCs). In fact, as recently demonstrated, BM-derived VSELs could be specified into hematopoietic lineage in co-cultures over OP-9 stroma cell support. 12 Furthermore, molecular analysis of VSELs revealed that their quiescence in adult BM and potentially premature depletion is controlled by epigenetic changes of some imprinted genes that regulate signaling of Ins/Igf (for example, Igf2-H19 locus, Igf2R and Rasgrf1).
13 Accordingly, we observed that murine BM-sorted VSELs erase the paternally methylated imprints (for example, DMRs at Igf2-H19 and Rasgrf1 loci); however, they hypermethylate the maternally methylated ones Table 1 Peripheral blood parameters in male 6-month-old normal and bGH transgenic mice (n ¼ 10) Letters to the Editor (for example., DMRs at Igf-2R). 13 This epigenetic reprogramming of genomic imprinting negatively affects Ins/Igf signaling and maintains the quiescence of VSELs and protects them from premature aging and tumor formation.
Our initial studies performed on normal 4-week-old and 2-year-old mice revealed that the number of VSELs and their pluripotentiality decrease during aging. 14, 15 To support this, VSELs from old mice show lower expression of the pluripotentiality master regulators such as Oct4, Nanog, Sox2, Klf4 and cMyc and at the molecular level the Oct4 promoter in VSELs becomes hypermethylated with age and shows a closed chromatin structure. Furthermore, VSELs from old mice show the somatic type of methylation at both Igf2-H19 and Rasgrf1 loci, which suggests their increased sensitivity to Ins/Igf signaling.
Based on this we became interested in a role of prolonged Ins/Igf signaling in homeostasis of a pool of BM-residing VSELs and VSEL-derived LT-HSCs. To address better a role of Ins/Igf signaling in homeostasis of a pool of VSELs and HSCs, we performed previously experiments in Laron dwarf mice. Owing to a deficiency of GH receptor (GHR), these animals display a severe reduction in the Igf1 plasma level and do not display increase in GH-mediated Igf1 plasma level in response to caloric uptake. Interestingly, these animals live 30-40% longer than their normal littermates. 3 Therefore, we measured the number of VSELs in the BM of 20-month-old murine Laron dwarfs (GHR À/À ) and corresponding normal heterozygous littermates (GHR þ /À ) by fluorescence-activated cell sorting. Interestingly, we noticed that the number of VSELs in the BM of Letters to the Editor plasma Igf1-deficient Laron dwarfs is maintained at a 3-4-fold higher level than that of normal GHR þ /À littermates during aging. 15 Our molecular analysis studies have additionally demonstrated that the Oct4 promoter in these animals shows also a higher level of demethylation. We also observed that Laron dwarf mice have in BM (i) an B3-fold increase in the number of Sca-1 þ c-kit þ lineage À (SKL) HSCs and (ii) up to fourfold higher number of clonogenic progenitors. 15 Of note, more recently we even found more pronounced differences in number of VSELs and HSPCs between 26-month-old Laron dwarf mice and their littermates (manuscript in preparation).
To extend these studies, we employed in the current work 'a reverse model' consisting of transgenic mice that overexpress bovine growth hormone (bGH) and thus, in contrast to Laron dwarf mice, display chronic elevation of Igf1 in PB. As already reported, due to increased Igf1 level these mice live much shorter than normal littermates (up to 1 year only) and frequently develop malignancies. 16 These animals are also significantly larger than normal controls and display several symptoms of acromegaly.
In the current study, 6-month-old phosphoenol pyruvate carboxykinase bGH (PEPCK-bGH) transgenic males and control normal animals were employed and we noticed that bGH transgenic mice are slightly anemic as compared with controls ( Table 1) . The low hematocrit level (Ht) and hemoglobin (Hb) concentration (Figure 1a ) in combination with normal number of erythrocytes are indicative of the presence of microcytic anemia in these animals. Transgenic mice had also slightly elevated platelet counts ( (Figures 1b and c) . However, at the same time, we did not observe differences in the number of clonogenic progenitors (CFU-GM, CFU-Meg) except for a slight decrease in the number of BFU-E, suggesting that defect in hematopoietic compartment was more profound at the level of most primitive HSCs than hematopoietic progenitor cells (Figure 1c ), but this reduced number of HSCs was still able to maintain a normal number of clonogenic progenitors. In parallel, we performed a molecular analysis of VSELs isolated from bGH transgenic and normal control mice. Figure 2a demonstrates that the Oct-4 promoter in 6-monthold bGH transgenic mice-derived VSELs is hypermethylated (B72%) to a level similar to that seen in HSCs. In contrast, the Oct-4 promoter in VSELs isolated from 6-month-old normal mice still shows a significant degree of hypomethylation (B30%). This suggests that VSELs in the BM of bGH transgenic mice significantly lost their pluripotential character. At the same time, DMR, which regulates expression of H19-Igf2 locus that is hypomethylated in normal mice-derived VSELs (B1%), becomes hypermethylated in VSELs isolated from the BM of 6-month-old bGH transgenic mice. This indicates loss of imprinting and its reversal to somatic pattern and enhanced autocrine expression of Igf2 in these cells during aging (Figure 2b) . Similarly, the DMR region for RasGrf1 locus, which encodes the GTP-exchange factor for H-Ras involved in Ins/Igf signaling, that remains hypomethylated in VSELs from normal mice becomes methylated in VSELs isolated from the BM of bGH transgenic animals, which again indicates restoration of somatic imprint at this locus (Figure 2c) Letters to the Editor in VSELs from bGH transgenic mice in combination with elevated plasma Igf1 level in these animals leads to premature depletion of these cells.
Overall, as the plasma Igf1 level is regulated in mice by caloric uptake and in humans by caloric uptake provided that protein uptake is also low, these data shed new light on caloric restriction, senescence and the size of HSC compartment. Based on our findings, we propose that chronically elevated levels of Igf1, resulting, for example, from high caloric uptake, may lead to premature depletion of the SC pool, including VSELs and HSCs, and thus be responsible for premature aging in mice.
Further studies are needed to link the effect of chronic high Igf1 signaling in VSELs with the enhanced frequency of cancer in bGH transgenic mice. As many human malignancies are activated by Igf1 and Igf2 signaling (for example, due to loss of heterozygosity or loss of imprinting at the Igf2-H19 locus), we hypothesize that excessive activation of VSELs in an Ins/Igfdependent manner could promote malignant transformation of these cells. 17 Based on our previously published data on Laron dwarf mice with low circulating levels of Igf1 and current observations in bGH transgenic mice with high circulating levels of Igf1, we postulate novel linkages between the Igf1 level, aging and the SC compartment (Figure 3 ). According to our hypothesis, early in development a population of VSELs would be deposited in developing organs as a backup for tissue-committed SCs that plays a role in rejuvenation of tissues and organ regeneration after damage. These cells seem to be protected from uncontrolled proliferation and age-related depletion by changes in imprinted genes that regulate Ins/Igf signaling. We hypothesize that the pool of VSELs residing in adult tissues including BM is regulated by the circulating Igf1 level. An increase in Igf1 level (for example., bGH transgenic animals, chronic high caloric uptake) would accelerate in an Ins/Igf-dependent manner an age-dependent depletion of the pool of VSELs and their potential to rejuvenate tissues (for example, in BM to supply LT-HSCs). By contrast, a low Igf1 level (for example, Laron dwarf mutants, caloric restriction) would have an opposite and protective effect on these cells leading to longevity.
Thus, these data further support our hypothesis that relates aging, longevity, insulin factor signaling and high caloric uptake to the abundance and function of pluripotent VSELs deposited in adult tissues. A decrease in the number of these cells will affect pools of tissue-committed SCs (for example, HSCs in BM) and have an impact on tissue rejuvenation and lifespan. Strategies to attenuate Ins/Igf stimulation of VSELs may lead to improved longevity.
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CD73 (5
0 -nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia Ecto-5 0 -nucleotidase, also known as CD73, is a glycosyl phosphatidylinositol-linked enzyme on the cell surface of a variety of cell types, 1,2 which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.
1 CD73, originally defined as a lymphocyte differentiation antigen, is thought to function as an adhesion molecule necessary for lymphocyte binding to endothelium 3 and a co-signaling molecule on T lymphocytes when ligated by antibodies. 1 Two earlier studies showed the expression of CD73 on childhood acute lymphoblastic leukemia (ALL) cells. 4, 5 The expression of CD73 in common ALL (C-ALL) and pre-B-ALL varied from absent to very high and was low or absent in T-lineage ALL, pro-B-ALL and mature B-ALL. Both our earlier studies suggested that a high expression of CD73 was related to a poor prognosis in pre-B-ALL and C-ALL. 4, 5 However, both studies were retrospective and included only small series of patients. Therefore, we evaluated prospectively whether CD73 predicts outcome in a recent treatment protocol for childhood ALL. The study was approved by the Institutional Review Board.
CD73 was measured on 411 bone marrow cells of children with ALL aged 1-18 years who were included in the Dutch Childhood Oncology Group (DCOG) (formerly the Dutch Childhood Leukemia Study Group) ALL-9 protocol and diagnosed between 22 May 1997 and 29 Apr 2001. Mononuclear cells were isolated on a Ficoll-isopaque gradient and used after cryopreservation as described before. 6 Immunofluorescence staining was performed with MoAb CD73 FITC conjugated. The CD73 antibody 7G2 was available, thanks to Linda F Thompson (Oklahoma, USA). 7 After rinsing twice, FITCconjugated rabbit antimouse immunoglobulin G with phosphate-buffered saline (PBS) þ 1% bovine serum albumin (BSA) was added for 30 min. Cells were rinsed twice and resuspended in 0.3 ml PBS/BSA/sodium azide. Fluorescence was measured with a FACScan (Becton Dickinson, San Jose, CA, USA).
All results were updated until August 2008. The primary end point was event-free survival (EFS). EFS was defined as the time from diagnosis to relapse, death in remission or the occurrence of a second tumor. Patients who did not achieve complete remission, either because of death in induction or because of resistant disease at the end of induction, were considered as treatment failures on day 0.
The immunophenotypic subclasses pre-B-ALL and C-ALL showed no significant difference in the expression of CD73 (median percentage of cells with CD73 expression, 32% and 37%, respectively, P ¼ 0.554). T-ALL showed a significant lower expression of CD73 compared with pre-B-ALL/C-ALL (P ¼ 0.000; Table 1 ). Four out of the five pro-B-ALL cases had a very low expression of CD73 and one had a very high expression (Figure 1) .
Further analysis was done only for the 338 patients with pre-B-ALL and C-ALL. Males and females showed no significant difference in the expression of CD73 (P ¼ 0.703; Table 1 ). Patients younger than 10 years of age showed no significant difference in the expression of CD73 compared with patients older than 10 years of age. Patients with a white-blood-cell count o20/ml did show a slight but significant lower expression of CD73 compared with patients with a white-blood-cell count 420/ml (P ¼ 0.050). Patients with central nervous system (CNS) involvement did not show a significant different expression of CD73 compared with patients without CNS involvement (P ¼ 0.487). Furthermore, patients with the different genetic abnormalities ETV6-RUNX1 t(12;21), BCR-ABL1 t(9;22), mixed lineage leukemia (MLL) rearrangement, t (1;19), hyperdiploid (50-60) or other cytogenetic mutations did not show different expressions of CD73 compared with cases with normal cytogenetics.
Pre-B-ALL/C-ALL patients were divided in two groups with low and high CD73 expression based upon the median value of
